# NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

> **NCT05262556** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Amr Mohamed MD** · enrollment: 15 (actual)

## Conditions studied

- Gastroenteropancreatic Neuroendocrine Tumor
- Gastroenteropancreatic Neuroendocrine Neoplasm
- Neuroendocrine Carcinoma
- Mixed Neuroendocrine-Non Neuroendocrine Neoplasm

## Interventions

- **DRUG:** NP-101 (TQ Formula)
- **DRUG:** Nivolumab (3mg/kg)
- **DRUG:** Ipilimumab (1mg/kg)

## Key facts

- **NCT ID:** NCT05262556
- **Lead sponsor:** Amr Mohamed MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-15
- **Primary completion:** 2025-12
- **Final completion:** 2026-06
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05262556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05262556, "NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05262556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*